243 related articles for article (PubMed ID: 23548309)
1. Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification.
Iida A; Kemmochi Y; Kakimoto K; Tanimoto M; Mimura T; Shinozaki Y; Uemura A; Matsuo A; Matsushita M; Miyamoto K
Am J Nephrol; 2013; 37(4):346-58. PubMed ID: 23548309
[TBL] [Abstract][Full Text] [Related]
2. The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats.
Matsuo A; Iida A; Tanimoto M; Matsushita M; Miyamoto K
Ren Fail; 2014 Sep; 36(8):1291-7. PubMed ID: 24975675
[TBL] [Abstract][Full Text] [Related]
3. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
Cozzolino M; Staniforth ME; Liapis H; Finch J; Burke SK; Dusso AS; Slatopolsky E
Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
[TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
5. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats.
Katsumata K; Kusano K; Hirata M; Tsunemi K; Nagano N; Burke SK; Fukushima N
Kidney Int; 2003 Aug; 64(2):441-50. PubMed ID: 12846739
[TBL] [Abstract][Full Text] [Related]
6. PA21, a new iron-based noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats.
Phan O; Maillard M; Peregaux C; Mordasini D; Stehle JC; Funk F; Burnier M
J Pharmacol Exp Ther; 2013 Aug; 346(2):281-9. PubMed ID: 23697346
[TBL] [Abstract][Full Text] [Related]
7. [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].
Nagano N; Miyata S; Abe M; Wakita S; Kobayashi N; Wada M
Clin Calcium; 2005 Sep; 15 Suppl 1():35-9; discussion 39-40. PubMed ID: 16272627
[TBL] [Abstract][Full Text] [Related]
8. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
Meng Y; Zhang H; Li Y; Li Q; Zuo L
Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
[TBL] [Abstract][Full Text] [Related]
9. Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
Phan O; Maillard M; Malluche HH; Stehle JC; Funk F; Burnier M
Biomed Res Int; 2015; 2015():515606. PubMed ID: 26221597
[TBL] [Abstract][Full Text] [Related]
10. Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Sato H; Goto M; Nishimura G; Morimoto N; Tokushima H; Horii Y; Takahashi N
Bone; 2023 Feb; 167():116613. PubMed ID: 36395959
[TBL] [Abstract][Full Text] [Related]
11. Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus.
Yi H; Fukagawa M; Yamato H; Kumagai M; Watanabe T; Kurokawa K
Nephron; 1995; 70(2):242-8. PubMed ID: 7566311
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis.
Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
J Ren Nutr; 2014 Jul; 24(4):261-7. PubMed ID: 24836401
[TBL] [Abstract][Full Text] [Related]
13. Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism.
Sakai M; Tokunaga S; Kawai M; Murai M; Kobayashi M; Kitayama T; Saeki S; Kawata T
PLoS One; 2020; 15(4):e0232428. PubMed ID: 32343734
[TBL] [Abstract][Full Text] [Related]
14. Fetuin-A decrease induced by a low-protein diet enhances vascular calcification in uremic rats with hyperphosphatemia.
Yamada S; Tokumoto M; Tsuruya K; Tatsumoto N; Noguchi H; Kitazono T; Ooboshi H
Am J Physiol Renal Physiol; 2015 Oct; 309(8):F744-54. PubMed ID: 26180236
[TBL] [Abstract][Full Text] [Related]
15. Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels.
Terai K; Nara H; Takakura K; Mizukami K; Sanagi M; Fukushima S; Fujimori A; Itoh H; Okada M
Br J Pharmacol; 2009 Apr; 156(8):1267-78. PubMed ID: 19302594
[TBL] [Abstract][Full Text] [Related]
16. PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure.
Yaguchi A; Tatemichi S; Takeda H; Kobayashi M
PLoS One; 2017; 12(7):e0180430. PubMed ID: 28704404
[TBL] [Abstract][Full Text] [Related]
17. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia.
Tamagaki K; Yuan Q; Ohkawa H; Imazeki I; Moriguchi Y; Imai N; Sasaki S; Takeda K; Fukagawa M
Nephrol Dial Transplant; 2006 Mar; 21(3):651-9. PubMed ID: 16311258
[TBL] [Abstract][Full Text] [Related]
18. JTT-751 for treatment of patients with hyperphosphatemia on peritoneal dialysis.
Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Hirakata H
Nephron Clin Pract; 2014; 128(1-2):135-40. PubMed ID: 25401266
[TBL] [Abstract][Full Text] [Related]
19. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial.
Yokoyama K; Hirakata H; Akiba T; Sawada K; Kumagai Y
Am J Nephrol; 2012; 36(5):478-87. PubMed ID: 23147696
[TBL] [Abstract][Full Text] [Related]
20. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure.
Denda M; Finch J; Slatopolsky E
Am J Kidney Dis; 1996 Oct; 28(4):596-602. PubMed ID: 8840952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
